Charles Bankhead on Muck Rack

Charles Bankhead

Verified
As seen in: MedPage Today, MSN, STAT, Everyday Health, Veterans Today, HCP Live, City of Hope, MDEdge, Modern Medicine, HealthLeaders, NewsBeezer and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Charles

Contact Charles, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Charles Bankhead’s Biography

Read Full Bio →

Working from Houston, home to one of the world's largest medical complexes, Charles Bankhead has more than 20 years of experience as a medical writer and editor. His career began as a science and medical writer at an academic medical center. He later spent almost a decade as a writer and editor for Medical World News, one of the leading medical trade magazines of its era. After a freelance career that spanned parts of three decades, he joined MedPage Today.

Articles

Aspirin and bladder cancer; oncology workforce shortage; 'exploding immune cells'

|
By Charles Bankhead Verified
| MSN Verified
; ; Continue reading More for You
Open in Who Shared View Duplicates (213) Issue with article?

Microsoft Cares About Your Privacy Too much or too little opioid pain relief may drive refills after urologic surgery

|
By Charles Bankhead Verified
| MSN Verified
Charles Bankhead WASHINGTON -- Too much or too little opioid pain management at discharge after urologic surgery significantly increased the likelihood of refills, providing new insight into opioid overuse, according to a study reported here. More than 60% of patients received discharge opioid prescriptions that were mismatched with their last in-hospital opioid dose, with underdosing accounting for a third of the mismatches.
Open in Who Shared View Duplicates (3) Issue with article?

Major complete response rate in very high-risk bladder cancer with combo treatment

|
By Charles Bankhead Verified
| MSN Verified
Charles Bankhead WASHINGTON -- Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in more than 90% of patients who had refused cystectomy for high-risk disease, a small prospective study showed. Only three of 37 patients did not have a CR at 6 months with pembrolizumab (Keytruda) and Bacille Calmette-Guérin (BCG). After a median follow-up of 22 months, no patient had progressed to MIBC or developed metastasis.
Open in Who Shared View Duplicates (3) Issue with article?
See all 201 licensed articles (1,224 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified